ELUT earnings
Elutia Inc. (ELUT) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery MarketNXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparationsBrought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scaleChief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant unmet need and market opportunityStrong balance sheet with $36.5 million in cash and escrowed proceeds from the BioEnvelope business divestitureConference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today reported a business update and financial res
- Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2026 financial results after market close on Thursday, May 14, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the op
- Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the
- Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development- Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the third quarter of 2025. Business Highlights: BioEnvelope Business Sold to Boston Scientific Corporation for $88 Million: Transaction closed October 1, 2025, with proceeds used to eliminate debt and fund NXT-41x development program.Advancing Nex
- Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the
- Elutia Delivers Robust Growth on the Strength of EluPro™ Market AdoptionEluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the second quarter of 2025. Since full launch in January 2025, EluPro has rapidly established itself as the preferred antibiotic bioenvelope choice in cardiac implantable electronic device procedures, delivering robust revenue growth and expanding access through national group purchasing organization
- Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13754773 Please log in approximately 10 minutes prior to the scheduled start time.
- Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13753035 Please log in approximately 10 minutes prior to the scheduled start time. A liv
- Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13751810 Please log in approximately 10 minutes prior to the scheduled
- Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use: Announced the first patient implant of EluPro, the FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators.Strong Initial Adoption: EluPro is being utilized across all major cardiac implantable electronic device (CIED) brands and in neurostimulation procedures. EluPro now accounts
- Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024SILVER SPRING, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a leader in drug-eluting biomatrix products, today announced that it will release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information. Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13749386 Please log in approximately 10 minutes prior to the scheduled start time. A l
- SWK Holdings Provides Portfolio UpdateCompany Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
- Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024SILVER SPRING, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today announced that it will release its second quarter 2024 financial results after market close on Wednesday, August 7, 2024. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13747696 Please log in approximately 10 minutes prior to the scheduled start time. A l
- SWK Holdings Highlights Recent Achievements and Provides Portfolio UpdateDALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st
- Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA ClearanceSILVER SPRING, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a company pioneering drug-eluting biomatrix products, today provided a business update and financial results for the first quarter ended March 31, 2024. Business Highlights: Generated strong revenue growth for proprietary product lines in the first quarter of 2024, led by SimpliDerm net sales increasing 55% compared to the first quarter of 2023FDA interactions regarding CanGarooRM, Elutia's antibiotic-eluting biologic envelope, continue to be positiveAddressing the final details for CanGarooRM clearance; anticipate FDA decision in the second quarter of 2024Preparing for launch of C
- Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024SILVER SPRING, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that it will release its first quarter 2024 financial results after market close on Thursday, May 9, 2024. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13746000 Please log in approximately 10 minutes prior to the scheduled start time. A live and archi
- Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company") today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023. Business Highlights: Achieved strong annual revenue growth for both proprietary product lines, with sales increasing for SimpliDerm by 38% and CanGaroo by 3.4%.Submitted a 510(k) premarket notification to the U.S. Food and Drug Administration ("FDA" or "Agency") for CanGarooRM, Elutia's next-generation drug-eluting biomatrix product.FDA review and interaction for CanGarooRM has resulted in no requests for additional data to date. The Company remains on trac
- Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024SILVER SPRING, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that it will release its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13744499 Please log in approximately 10 minutes prior to the scheduled start
- Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results- Anticipate 510(k) filing for transformational Drug-Eluting Biomatrix CanGarooRM in Fourth Quarter SILVER SPRING, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2023. Business Highlights: Successfully completed transformation to Elutia, establishing a high growth company dedicated to developing and marketing propriety drug eluting biomatrices.Achieved a significant 44% year-over-year increase in SimpliDerm® net sales and an 11% year-over-year growth in CanGaroo® net sales.Divested Orthobiologics business u
- Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023SILVER SPRING, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that it will release its third quarter 2023 financial results after market close on Monday, November 13, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13742087 Please log in approximately 10 minutes prior to the scheduled start time. A live and